Related Experiment Video
Updated: May 12, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Benznidazole prevents endothelial damage in an experimental model of Chagas disease
Alfredo Molina-Berríos1, Carolina Campos-Estrada, Michel Lapier
1Centro de Investigación Biomédica, Facultad de Medicina, Universidad Diego Portales, Av. Ejercito 141, Santiago, Chile.
Objectives:
To evaluate the effect of benznidazole on endothelial activation in a murine model of Chagas disease.
Methods:
A low (30mg/kg/day) and a high (100mg/kg/day) dose of benznidazole were administered to mice infected with Trypanosoma cruzi during the early phases of the infection. The effects of the treatments were assessed at 24 and 90 days postinfection by evaluating the parasitaemia, mortality, histopathological changes and expression of ICAM in the cardiac tissue. The blood levels of thromboxane A2, soluble ICAM and E-selectin were also measured. T. cruzi clearance was assessed by the detection of parasite DNA in the heart tissue of infected mice.
Results:
Benznidazole decreased the cardiac damage induced by the parasite, and amastigote nests disappeared at 90 days postinfection. Both doses cleared the parasite from the cardiac tissue at 24 and 90 days postinfection. In addition, benznidazole decreased the thromboxane levels and normalized the plasma sICAM and sE-selectin levels by 90 days postinfection.
Conclusions:
Early administration of benznidazole at a dose as low as 30mg/kg eradicates T. cruzi from cardiac tissue. Additionally, benznidazole prevents cardiac damage and modulates endothelial activation as part of its antichagasic activity.
Related Concept Videos
Anthelminthic Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

